Research (Principal Investigator)
- A phase II randomized, double-blinded, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.
- A phase II randomized, double-blinded, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer with bone metastases treated with the standard-of-care treatment exemestane and everolimus.
- Determining the feasibility of Peptide Receptor Radionuclide Therapy by means of Gallium 68 DOTAPEPTDE PET/ CT Imaging in non-radioiodine-avid differentiated thyroid carcinoma patients.
- “Is the partition model superior to empirical BSA method for delivery of Yttrium-90 resin microspheres in hepatocellular carcinoma?”
- Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer.
- 18-Fluoromethylcholine PET/CT in the pre and post treatment evaluation of prostate cancer.
- Technetium-99m labeled Isoniazid planar whole body imaging coupled with hybrid Single Photon Emission Computed Tomography / Computed Tomography (SPECT/CT) imaging for active tuberculosis infections. Proof of clinical concept.